Brightseed, Inc. (South San Francisco, CA), the AI-native life sciences company, has announced the launch of the Brightseed Innovation Platform—the first continuous, AI-powered Health Sciences Innovation Platform designed to increase the probability of commercial success across health and life sciences.

With this launch, Brightseed said it formally evolves from a discovery-focused bioactives company into a platform-based enterprise AI company delivering software and data-asa-service (Saas and Daas) to global health science organizations. The business evolution is built on the technology and learnings that has allowed Brightseed to produce the first clinically validated, AI discovered compounds in the commercial market.

Across health and life sciences, more than 75 percent of early product ideas fail to reach market due to fragmented workflows, disconnected data, and late-stage risk discovery. Innovation has historically been structured as episodic project work rather than a connected, compounding capability.

According to the company, the Brightseed Innovation Platform rebuilds that model from the ground up. It connects discovery, development and commercialization within a unified architecture that preserves scientific insight, evidence, and decision context across the innovation lifecycle—transforming innovation from a gamble into a strategic growth engine.

At its core is Forager, Brightseed’s proprietary AI-powered discovery engine built on the world’s largest proprietary bioactive dataset spanning more than 11 million natural compounds across 23 health territories. Unlike general-purpose AI systems trained on public data, Brightseed’s platform is grounded in proprietary biological intelligence designed specifically for scientific rigor, traceability and defensibility, the company said.

“Health innovation has operated on a broken probability curve for decades,” said Lee Chae, PhD, co-founder and chief executive officer of Brightseed. “We built the Brightseed Innovation Platform to fundamentally change that curve. By converging deep biological insight, proprietary multi-omics data assets, and cutting-edge AI and machine learning architecture into a continuous innovation foundation, we are defining a new category—one where AI is not an add-on, but the core operating foundation of life sciences innovation.”

For more information, visit www.brightseedbio.com.